<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851225</url>
  </required_header>
  <id_info>
    <org_study_id>12 559 15</org_study_id>
    <nct_id>NCT02851225</nct_id>
  </id_info>
  <brief_title>Coordinate Regulation of Transfusions by Uploading</brief_title>
  <acronym>RTT</acronym>
  <official_title>Coordinate Regulation of Transfusions by Uploading</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently in the Toulouse University Hospital, the organization of transfusion care for&#xD;
      patients requiring regular transfusions is based on reading the biological results received&#xD;
      by fax before confirming or disproving a planned hospitalization or program a new hospital if&#xD;
      needed.&#xD;
&#xD;
      Remote transmission of laboratory results, replacing fax communication might facilitate the&#xD;
      coordination of care that results from these laboratory results and provide a better respect&#xD;
      of the Plan Custom Care Transfusion (PPST).&#xD;
&#xD;
      The investigators offer organization of transfusion supportive care for patients with&#xD;
      conditions requiring biological monitoring using the techniques of information and&#xD;
      communication telemedicine.&#xD;
&#xD;
      Primary objective&#xD;
&#xD;
      - Assess the feasibility of setting up an upload procedure biological results in the&#xD;
      treatment of transfusion supportive care.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  Assess the evolution of the quality of life of patients during the treatment&#xD;
&#xD;
        -  Assess changes in patient satisfaction over the support&#xD;
&#xD;
        -  Assess the evolution of the satisfaction of the medical team at home and at Toulouse&#xD;
           University Hospital&#xD;
&#xD;
        -  Describe the programming time (hospitalization, consultations)&#xD;
&#xD;
        -  Estimate the loss of biological results&#xD;
&#xD;
        -  Assessment of the descriptive use of hospitalization, consultation and biological&#xD;
           examinations in both groups. This remedy shall be valued in Euros thanks to GHS rates&#xD;
           for hospitalizations, general nomenclature for Professional acts (NGAP) and biology&#xD;
           nomenclature (NABM) for biological tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Setting up a Custom Care Plan for patients with conditions requiring a transfusion followed ,&#xD;
      which in its development provides a transfusion Care Custom Program .&#xD;
&#xD;
      The establishment of an electronic transmission enables the regulation of all&#xD;
      hospitalizations throughout the patient care pathway and reinforces the link city / hospital&#xD;
      through the receipt of laboratory results and issuing information to the partners of the care&#xD;
      network patient. The PPST will be transmitted by secure messaging.&#xD;
&#xD;
      The primary endpoint is the proportion of transfusion episodes where PPST is respected. The&#xD;
      proportion of patients whose care meets the PPST for 3 successive transfusion episodes will&#xD;
      also be estimated.&#xD;
&#xD;
      The secondary endpoints are:&#xD;
&#xD;
        -  The Patient satisfaction questionnaires (relative to the consideration of the results,&#xD;
           the management procedures) in 3 successive transfusions.&#xD;
&#xD;
        -  The Quality of life of the patient assessed by questionnaire (EORTC-QLQC30 and EQ5D) at&#xD;
           baseline and after 3 successive transfusion episodes.&#xD;
&#xD;
        -  The Satisfaction surveys of the medical team at home and the service effector&#xD;
           transfusion at baseline and after 3 successive transfusion episodes.&#xD;
&#xD;
        -  The Response time for a hospitalization or consultation program on the study period.&#xD;
&#xD;
        -  The Number of lost biological results.&#xD;
&#xD;
        -  Evaluation of the descriptive use of hospitalization, consultation, biology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Actual">May 11, 2021</completion_date>
  <primary_completion_date type="Actual">May 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of transfusion episodes in the Plan Custom Care Transfusion</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint chosen is the proportion of transfusion episodes where the Plan Custom Care Transfusion is respected. The element determining compliance will be:&#xD;
- Transfusion with remote transmission, and transfusion in a service defined in the Plan Custom Care Transfusion and transfusion with achievement of target hemoglobin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the evolution of the quality of life of patients ( EORTC- QLQC30 questionnaires and EQ5D )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>Assess changes in patient satisfaction ( satisfaction survey compared to the overall care , the inclusion of the results, the management procedures )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of medical team</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the evolution of the satisfaction of the medical team at home and in Hospital ( satisfaction surveys )</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neoplasm, Uncertain Whether Benign or Malignant</condition>
  <arm_group>
    <arm_group_label>telemedicine transmission</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telemedicine transmission of biological results in the treatment of transfusion supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without telemedicine transmission</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telemedicine transmission of biological results</intervention_name>
    <description>telemedicine transmission of biological informations</description>
    <arm_group_label>telemedicine transmission</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving blood transfusions and / or platelet on our hospital&#xD;
&#xD;
          -  Patient agreeing to participate in the project&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient who can not fill questionaries.&#xD;
&#xD;
          -  Absence of social coverage .&#xD;
&#xD;
          -  Patient under guardianship or trusteeship safeguard justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile Beyne Rauzy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IUCT-O</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

